Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/34874
Title: Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
Authors: Ann Lii Cheng
Deepak Amarapurkar
Yee Chao
Pei Jer Chen
Jean François Geschwind
Khean L. Goh
Kwang Hyub Han
Masatoshi Kudo
Han Chu Lee
Rheun Chuan Lee
Laurentius A. Lesmana
Ho Yeong Lim
Seung Woon Paik
Ronnie T. Poon
Chee Kiat Tan
Tawesak Tanwandee
Gaojun Teng
Joong Won Park
National Taiwan University Hospital
Bombay Hospital and Medical Research Centre
Veterans General Hospital-Taipei
National Taiwan University College of Medicine
The Johns Hopkins School of Medicine
University of Malaya
Yonsei University College of Medicine
Kindai University School of Medicine
University of Ulsan, College of Medicine
Universitas Indonesia
Samsung Medical Center, Sungkyunkwan University
SungKyunKwan University, School of Medicine
The University of Hong Kong
Singapore General Hospital
Mahidol University
Southeast University
National Cancer Center, Gyeonggi
Keywords: Medicine
Issue Date: 1-Jan-2014
Citation: Liver International. Vol.34, No.2 (2014), 174-183
Abstract: Patients with unresectable hepatocellular carcinoma (HCC) usually receive transarterial chemoembolization (TACE) or systemic therapies with intermediate and advanced-stage disease. However, intermediate-stage HCC patients often have unsatisfactory clinical outcomes with repeated TACE and there is considerable uncertainty surrounding the criteria for repeating or stopping TACE treatment. In July 2012, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was re-convened in Shanghai in an attempt to provide a consensus on the practice of TACE, particularly in regard to evaluating TACE 'failure'. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies for intermediate HCC. This review summarizes the evidence discussed at the meeting and provides expert recommendations regarding the use of TACE for unresectable intermediate-stage HCC. A key consensus of the Expert Panel was that the current definitions of TACE failure are not useful in differentiating between situations where TACE is no longer effective in controlling disease locally vs. systemically. By redefining these concepts, it may be possible to provide a clearer indication of when TACE should be repeated and more importantly, when TACE should be discontinued. © 2013 John Wiley & Sons A/S.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84891826857&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/34874
ISSN: 14783231
14783223
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.